Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alzheimer; Early Onset Clear all
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

NCT04100889
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 22, 2026, 4:21 PM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Completed No phase listed Observational

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

NCT04733989
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jul 22, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634
View directory record Official record
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Active, not recruiting Phase 1 Interventional

PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

NCT06750432
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
PMN310, Placebo
Drug
Lead sponsor
ProMis Neurosciences, Inc
Industry
Eligibility
50 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
22
States / cities
Irvine, California • Long Beach, California • Atlantis, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug (SC), Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

NCT04552795
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
3TC
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 22, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

NCT03634007
View directory record Official record
Conditions
Alzheimer Disease, Early Onset Alzheimer Disease
Interventions
LX1001
Biological
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Maitland, Florida • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 22, 2026, 4:21 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

NCT04623242
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Jul 22, 2026, 4:21 PM EDT
Completed No phase listed Observational

Tau Imaging in Young Onset Dementia

NCT02289118
View directory record Official record
Conditions
Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
Interventions
[18F]-T807 imaging tracer
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jul 22, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Dasatinib + Quercetin, Placebo Capsules
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

NCT05573490
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Cognitive Training, Tai Chi- Qi Gong, Brain Games, Stretching
Device · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of PTI-125 in Healthy Volunteers

NCT03784300
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease
Interventions
50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Jul 22, 2026, 4:21 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

NCT03625401
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
AD-35 60mg group, Placebo group
Drug
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Sacramento, California • San Diego, California • Delray Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jul 22, 2026, 4:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Interactive Physical and Cognitive Exercise System

NCT03069391
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment, Neurocognitive Disorder, Cognitive Impairment, Cognitive Change
Interventions
physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
Behavioral · Device
Lead sponsor
Union College, New York
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 22, 2026, 4:21 PM EDT
Completed No phase listed Observational

Early Onset Alzheimer's Disease Genomic Study

NCT03645993
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Genetic Testing
Genetic
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease

NCT05052866
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Social Robot
Behavioral
Lead sponsor
DreamFace Technologies, LLC
Industry
Eligibility
65 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 22, 2026, 4:21 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT06647498
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug, Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Juice Plus Supplement Clinical Trial

NCT04656860
View directory record Official record
Conditions
Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Juice Plus+
Dietary Supplement
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 22, 2026, 4:21 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 22, 2026, 4:21 PM EDT
Not listed Not applicable Interventional

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

NCT03661034
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Memory Disorders, Memory Loss, Memory Impairment, Memory Disorders, Age Related, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia, Mild, Dementia, Alzheimer Type, Cognitive Decline
Interventions
GammaSense Stimulation System (non-invasive, non-significant risk)
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Jul 22, 2026, 4:21 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

NCT05655195
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes), Alzheimer's, Alzheimer's Disease
Interventions
GENUS device (Active Settings), GENUS device (sham settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
65 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 22, 2026, 4:21 PM EDT